Skye Bioscience, Inc. (SKYE) financial statements (2022 and earlier)

Company profile

Business Address 11250 EL CAMINO REAL, SUITE 100
SAN DIEGO, CA 92130
State of Incorp. NV
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments8,9832,4691,8301,853260653,221
Cash and cash equivalents8,9832,4691,8301,853260653,221
Restricted cash and investments555543838
Receivables13      
Prepaid expense55419015393291170159
Other current assets57083 736
Total current assets:9,6122,6641,9951,9545562793,454
Noncurrent Assets
Operating lease, right-of-use asset147  
Property, plant and equipment8872311013
Other noncurrent assets8    3444
Total noncurrent assets:24372314457
TOTAL ASSETS:9,8552,6721,9971,9575573233,511
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities1,242364130200299541400
Accounts payable89836413016101275125
Accrued liabilities   11814499229
Employee-related liabilities344  665516746
Debt1,97564  235  
Derivative instruments and hedges, liabilities603941115,739   
Due to related parties21710    
Deferred revenue and credits 2 
Other liabilities376259420    
Other undisclosed current liabilities25744  272119182
Total current liabilities:3,91278797115,939806662582
Noncurrent Liabilities
Long-term debt and lease obligation791,4343871,361   
Long-term debt, excluding current maturities 1,4343871,361   
Operating lease, liability79  
Liabilities, other than long-term debt  912195511,1122,458
Deferred revenue and credits  3
Derivative instruments and hedges, liabilities  912195511,1122,455
Other undisclosed noncurrent liabilities(79)      
Total noncurrent liabilities:791,4344781,5805511,1122,458
Total liabilities:3,9912,2211,44917,5191,3571,7743,040
Stockholders' equity
Stockholders' equity attributable to parent5,864451548(15,562)(3,570)(2,914)(892)
Common stock476288183134342220
Additional paid in capital52,64438,89732,53816,2319,4457,1636,087
Accumulated deficit(47,256)(38,734)(32,173)(33,225)(14,031)(10,937)(7,758)
Warrants and rights outstanding   1,298983838759
Other undisclosed stockholders' equity    2,7691,4631,363
Total stockholders' equity:5,864451548(15,562)(800)(1,451)471
TOTAL LIABILITIES AND EQUITY:9,8552,6721,9971,9575573233,511

Income statement (P&L) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Operating expenses(7,848)(6,289)(6,633)(4,693)(3,859)(4,471)(4,317)
Operating loss:(7,848)(6,289)(6,633)(4,693)(3,859)(4,471)(4,317)
Nonoperating income (expense)(672)(270)7,6860   
Investment income, nonoperating0000   
Interest and debt expense118(706)(725)(685)(1)(52)(585)
Other undisclosed income (loss) from continuing operations before equity method investments, income taxes 706725(13,815)767  
Income (loss) from continuing operations before equity method investments, income taxes:(8,402)(6,559)1,053(19,193)(3,093)(4,522)(4,902)
Other undisclosed income (loss) from continuing operations before income taxes(118)    1,34663
Income (loss) from continuing operations before income taxes:(8,520)(6,559)1,053(19,193)(3,093)(3,176)(4,839)
Income tax expense(2)(2)(2)(2)(2)(2)(2)
Net income (loss) attributable to parent:(8,522)(6,561)1,052(19,194)(3,094)(3,178)(4,841)
Preferred stock dividends and other adjustments    (1,044)(325) 
Net income (loss) available to common stockholders, diluted:(8,522)(6,561)1,052(19,194)(4,138)(3,503)(4,841)

Comprehensive Income ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net income (loss):(8,522)(6,561)1,052(19,194)(3,094)(3,178)(4,841)
Comprehensive income (loss), net of tax, attributable to parent:(8,522)(6,561)1,052(19,194)(3,094)(3,178)(4,841)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: